D.5What is the safety and efficacy of antimuscarinics compared with a) placebo or treatment as usual b) other antimuscarinics for the treatment of incontinence due to neurological disease/overactive bladder due to neurological disease?

Review Protocol - IND
ComponentDescription
PopulationNeurological disease
Patients with neurogenic detrusor over activity
Patients with reduced bladder compliance
InterventionAntimuscarinics
ComparisonPlacebo or treatment as usual
Other antimuscarinics
OutcomesFrequency of voiding by day and night.
Number of incontinence episodes per week.
Quality of life.
Patients and carers’ perception of symptoms.
Adverse events, including urinary tract infections, renal complications and unscheduled hospital admissions.
Treatment adherence
Kidney function (hydronephrosis)
Maximum cystometric capacity
Bladder compliance
Residual urine
ExclusionIncontinence due to non-neurological cause (abstracts selected only if entire population specified as neurological)
N < 20
Search strategyThe databases to be searched are Medline, Embase, The Cochrane Library, CINAHL
All years
Studies will be restricted to English language only
Search termsAnticholinergics: Darifenacin, flavoxate hydrochloride, oxybutynin hydrochloride, propantheline bromide, propiverine hydrochloride, solifenacin succinate, tolterodine tartrate, tropsium chloride, atropine
Antimuscarinics are also known as anticholinergics
The review strategyRCTs and for adults and
Kidney function and adverse events observational studies for adults.
RCTs and observational studies for children
AnalysisSubgroups
By condition
Adults analysed separately to children

From: Appendix D, Review Protocols

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.